This indefinite-delivery, indefinite-quantity (IDIQ) contract was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases, to Glaxosmithkline, LLC, a pharmaceutical company, for the purchase of 12 standard adult vaccines. The $172.4 million contract has a one-year period of performance from July 1, 2022 to June 30, 2023 and does not utilize any set-asides. The vaccines, which include influenza, hepatitis, pneumococcal, and meningococcal products, will be used to support CDC immunization awardees, such as state health departments, in their adult vaccination programs authorized under the Public Health Service Act. Delivery orders must be fulfilled within 15 business days, and the vaccines must have a minimum 12-month shelf life. The solicitation was conducted in accordance with Federal Acquisition Regulation (FAR) Parts 12 and 15 procedures, and no set-aside designation was used for this procurement.
The contract serves as a multiple award IDIQ vehicle, allowing the CDC to place delivery orders for varying quantities of each vaccine type as needed to meet public health requirements. Associated task orders and pricing will further specify the delivery timelines and quantities based on the CDC's immunization program needs. This contract builds upon Glaxosmithkline's existing federal contract portfolio, which includes vaccine and pharmaceutical supply agreements with agencies such as the Departments of Defense, Veterans Affairs, and Health and Human Services.
Generated 12/31/24, 2:05 PM